ClinicalTrials.gg
CompletedNCT06332664T-NICEUpdated Nov 19, 2025

Collaborative Tele-Nutritional Care for Patient With Stage IV Cancer

An interventional study of Early Nutrition Intervention in Nutrition, sponsored by Xingchen Peng. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Xingchen Peng · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In China, the treatment of advanced-stage cancer often follows a pattern where the management of patients is primarily overseen by oncologists who focus on addressing the main clinical symptoms and intervening accordingly.

However, symptoms such as appetite loss, weight loss, and anxiety are often overlooked. It is common for clinical nutritionists to passively enter oncology wards to conduct comprehensive nutritional assessments and develop nutrition plans only when patients exhibit significant malnutrition, upon request from oncologists or patients and their families.

Against this background, the investigators integrated clinical nutritionists into the oncology treatment team and established a proactive nutritional intervention team specifically targeting stage IV cancer patients. This initiative aims to conduct a single-center, open-label, randomized parallel-group prospective study, with the following objectives: 1) to evaluate the impact of this model on the nutritional status, survival, and quality of life of advanced-stage cancer patients, and 2) to further optimize this model for widespread replication in clinical practice.

02

Conditions studied

  • Nutrition

Keywords

  • cancer cachexia
03

In context

Lead sponsor

Xingchen Peng is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patients should be at the range of 18-80 years old, (ECOG) 0-1.
  2. The patients should be diagnosed, untreated stage IV cancer patients requiring chemotherapy;
  3. The patients should have good cognitive and reading abilities to complete questionnaires;
  4. The patients should have ≥3 months expected survival period

Exclusion criteria

Exclusion Criteria:

  1. Patients with neurological or psychiatric disorders affecting cognitive function, including central nervous system from tumors;
  2. Patients with severe diseases affecting digestion, metabolism, or food intake;
  3. Presence of to chemotherapy;
  4. Patients in a cachectic state or cachexia;
  5. Patients with PG-SGA score ≥9 points
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Early Nutrition Intervention

    For patients meeting the inclusion criteria and randomly assigned to the intervention group, the investigators will assess their nutritional status monthly. During the home-based period between chemotherapy cycles, the investigators will conduct follow-up and provide care using a mobile application (APP). In the event of new nutritional risks emerging in patients, timely recommendations for medical consultation will be made, and nutritional plans will be formulated accordingly.

    Combination Product: Early Nutrition Intervention

  • No intervention
    standard care

    Patients randomly assigned to the standard treatment group will receive standard care for cancer patients and will not be scheduled for interdisciplinary supportive therapy assessment unless requested by the patient, the primary oncologist, or their family.

Interventions

  • Combination productEarly Nutrition Intervention

    This involves a multidisciplinary team intervention, including oncologists, nutritionists, and nurses. Additionally, the intervention introduces a team-developed mobile application (APP) for the purpose of regular patient follow-ups to identify nutritional risks promptly and facilitate timely interventions. Patients identified as at risk through the app follow-up will be referred to the nutrition clinic for consultation to address nutritional concerns. For advanced-stage cancer patients undergoing monthly chemotherapy hospitalizations, comprehensive assessments encompassing nutrition, psychological aspects, and other facets will be conducted during hospital stays. When deemed necessary, patients will receive dietary guidance and nutritional support.

06

What researchers measure

Primary outcomes

  1. the incidence of cachexia

    The definition and classification of cancer cachexia was used by an international consensus \[9, 10\]: (1) weight loss \> 5% over the past 6 months (in the absence of simple starvation), (2) BMI \< 20 and any degree of weight loss \> 2%, or (3) appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \> 2%. The assessment of skeletal muscle depletion was used by mid-upper arm muscle area by anthropometry (men \< 32 cm2, women \< 18 cm2)

    Time frame: every month, up to half year

Secondary outcomes

  1. body weight

    Changes in body weight over 6 months

    Time frame: every month, up to half year

  2. Nutritional risk and malnutrition status

    Nutrition Risk Screening 2002 (NRS2002) ,the minimum value is 0 and maximum value is 7, and higher scores mean a worse outcome.

    Time frame: every month, up to half year

  3. Nutritional risk and malnutrition status

    Patient-Generated Subjective Global Assessment (PG-SGA),the minimum value is 0 and maximum value is 20, and higher scores mean a worse outcome.

    Time frame: every month, up to half year

07

Study locations

1 site
  • West China Hospital, Sichuan Universit
    Chengdu, Sichuan 610041, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Aug 2025, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2024
First posted
Mar 27, 2024
StartActual
Mar 28, 2024
Primary completionActual
Aug 30, 2025
CompletionActual
Aug 30, 2025
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06332664
Lead sponsor
Xingchen Peng
Responsible party
Xingchen Peng (PhD, Professor, West China Hospital) — Sponsor-investigator
First posted
Mar 27, 2024
Start date
Mar 28, 2024
Primary completion
Aug 30, 2025
Completion
Aug 30, 2025
Last update
Nov 19, 2025

Study contacts

XingChen Peng, Ph.D
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion